Oct. 10 at 5:50 PM
$OVID surges 39.2% on promising Phase I epilepsy study results! 🚀
OV329, Ovid's lead candidate, shows strong GABAergic activity, boosting inhibition by up to 53% on the APB muscle. This breakthrough could position OV329 as a best-in-class seizure treatment.
See what makes this a compelling buy with Zacks Rank #2 👉 https://www.zacks.com/stock/news/2766357/ovid-stock-soars-39-in-a-month-following-upbeat-epilepsy-study-data?cid=sm-stocktwits-2-2766357-body-15657&ADID=SYND_STOCKTWITS_TWEET_2_2766357_BODY_15657